普莱柯(603566) - 2021 Q1 - 季度财报

Financial Performance - Operating revenue for the period was CNY 308,684,677.37, representing a year-on-year growth of 59.81%[12] - Net profit attributable to shareholders was CNY 86,849,170.37, up 46.21% from the same period last year[12] - Basic earnings per share rose by 55.56% to CNY 0.28[12] - The company's operating revenue for Q1 2021 was CNY 159,481,775.01, an increase from CNY 105,745,260.14 in Q1 2020, representing a growth of approximately 50.8%[50] - The net profit attributable to shareholders for Q1 2021 was CNY 86,849,170.37, compared to CNY 59,400,827.59 in Q1 2020, reflecting an increase of about 46.2%[49] - The total profit for Q1 2021 was CNY 101,678,458.31, compared to CNY 67,040,371.34 in Q1 2020, representing an increase of approximately 51.6%[49] - The total comprehensive income for Q1 2021 was CNY 86,849,170.37, compared to CNY 59,400,827.59 in Q1 2020, indicating an increase of about 46.2%[50] Revenue Breakdown - Revenue from pig vaccines surged by 191.13% to CNY 110,235,441.30 compared to the previous year[15] - Revenue from chemical drugs increased by 63.22% to CNY 100,298,781.19 year-on-year[15] - Operating revenue rose by 59.81% to ¥308,684,677.37 compared to ¥193,156,705.35, primarily driven by sales of veterinary biological products and chemical drugs[21] Cash Flow - The net cash flow from operating activities was negative at CNY -14,564,672.22, a decline of 640.38% compared to the previous year[12] - Operating cash inflow totaled CNY 233,335,334.97, an increase from CNY 164,741,820.69 year-over-year[58] - Operating cash outflow amounted to CNY 247,900,007.19, compared to CNY 162,046,556.19 in the previous year[58] - Cash flow from investing activities showed a net outflow of CNY -52,913,502.84, contrasting with a net inflow of CNY 176,152,112.24 in the previous year[60] - Cash flow from financing activities resulted in a net outflow of CNY -100,004,090.87, consistent with the previous year's outflow[60] Assets and Liabilities - Total assets at the end of the reporting period reached CNY 2,117,453,881.78, an increase of 4.37% compared to the end of the previous year[12] - Non-current assets totaled ¥1,167,747,772.84, up from ¥1,149,343,204.16, indicating a growth in long-term investments[30] - Total liabilities amounted to ¥320,959,429.16, slightly increasing from ¥319,158,363.35, reflecting stable financial leverage[33] - The company's total liabilities decreased to ¥207,189,424.84 from ¥213,673,007.42, a reduction of approximately 3%[41] Shareholder Information - The company reported a total of 12,807 shareholders at the end of the reporting period[15] - The top shareholder, Zhang Xuke, holds 33.47% of the shares, totaling 107,619,672 shares[15] Expenses - Operating costs increased by 42.00% to ¥97,889,843.70 from ¥68,937,426.28, reflecting higher sales volumes[21] - Sales expenses surged by 102.17% to ¥66,530,190.77 from ¥32,907,838.56, attributed to increased marketing expenses[21] - Research and development expenses in Q1 2021 amounted to ¥19,883,507.77, compared to ¥16,846,927.91 in Q1 2020, indicating a 17.9% increase[44] - Research and development expenses for Q1 2021 were CNY 12,468,104.83, slightly up from CNY 11,595,555.03 in Q1 2020, showing a year-over-year increase of about 7.5%[50] Other Income and Losses - Other income decreased by 80.17% to ¥990,002.15 from ¥4,991,297.68, primarily due to reduced government subsidies related to daily operations[21] - Investment income fell by 57.43% to ¥875,665.33 from ¥2,057,077.35, mainly due to decreased returns from associated companies[21] - The company incurred a credit impairment loss of CNY 1,909,521.53 in Q1 2021, compared to CNY 2,095,828.79 in Q1 2020, reflecting a decrease of approximately 8.8%[49] - The company's other income for Q1 2021 was CNY 990,002.15, significantly lower than CNY 4,991,297.68 in Q1 2020, indicating a decline of about 80.2%[49] Inventory and Accounts - Accounts receivable increased by 42.57% to ¥292,426,520.56 from ¥205,117,342.36 due to increased revenue[21] - Inventory and contract assets rose to ¥91,418,376.91 from ¥71,772,524.63, marking a 27.4% increase[41] - The company reported a decrease in accounts payable from ¥22,167,632.28 in Q1 2020 to ¥20,581,035.94 in Q1 2021, a decline of 7.2%[41]